A case of an elderly female who developed subacute pleuropericarditis following BNT162b2 mRNA COVID-19 vaccination

Tatsuya Mizoguchi (MD), Masashi Yokoi (MD) *, Yasuhiro Shintani (MD), Junki Yamamoto (MD), Kento Mori (MD), Hiroshi Fujita (MD), Tsuyoshi Ito (MD), Tomonori Sugiura (MD), Yoshihiro Seo (MD, FJCC)

Department of Cardiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

ABSTRACT

Despite the established safety of BNT162b2 coronavirus disease 2019 (COVID-19) vaccine, some rare but serious complications have been previously reported. Here, we report a rare case of an elderly female who developed subacute pleuropericarditis after the vaccination. An 88-year-old female experienced weight gain and dyspnea three days after the second dose of BNT162b2 vaccination, and one month later, presented to our hospital due to the exacerbation of the symptoms. Computed tomography showed remarkable pericardial and bilateral pleural effusions, and transthoracic echocardiogram visualized collapse signs of right and left atrium which indicates pre-tamponade. Percutaneous drainages of pericardial and pleural effusions stabilized her vital condition and revealed that all of them were exudative, indicating the presence of pleuropericarditis. Finally, we diagnosed this case as COVID-19 vaccine-associated pleuropericarditis because there were no signs of bacterial/viral infection or any other relevant causes except for the vaccination. When the pericardial and pleural effusions are concurrently found after COVID-19 vaccination, vaccine-associated pleuropericarditis should be considered as a differential diagnosis. The aggressive drainage of pericardial and pleural effusions could be helpful not only for diagnosis but also for treatment in the clinical management of COVID-19 vaccine-associated pleuropericarditis.

Learning objective: Although the safety and efficacy of BNT162b2 have been widely accepted, it is clinically important to know the potential risk of side effects. When the pericardial and pleural effusions are concurrently found after COVID-19 vaccination, vaccine-associated pleuropericarditis should be considered as a differential diagnosis.

Case report

An 88-year-old Japanese female experienced chest discomfort, dyspnea, and gain of weight three days after the second dose of BNT162b2 vaccination (COMIRNATY®, BioNTech/Pfizer, Mainz, Germany/New York, NY, USA). In the local clinic, although cardiomegaly on chest X-ray and the small amount of pericardial effusion on transthoracic echocardiogram were pointed out, she was observed without any medication. One month later, she was referred to our hospital by the clinic due to the exacerbation of dyspnea. She had no prior history of cardiac disease, pleural disease, hypothyroidism, autoimmune disease, or neoplasm.

* Corresponding author at: Department of Cardiology, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuhocho, Nagoya, Aichi 4678601, Japan. E-mail address: yokojasmine@gmail.com (M. Yokoi).

https://doi.org/10.1016/j.jccase.2022.04.020
1878-5409/© 2022 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
Initial vital signs were as follows: a body temperature of 36.3 °C, O₂ saturation of 89% on room air with a respiratory rate of 20 breaths/min, heart rate of 82 beats/min, and blood pressure of 110/60 mm Hg. Physical examination revealed jugular venous distension and bilateral leg edema. The presence of a paradoxical pulse was not apparent, and a pericardial friction rub was not audible. Chest X-ray showed an enlarged cardio-thoracic ratio of 76.3% and bilateral pleural effusions. Chest computed tomography (CT) scan presented remarkable pericardial and bilateral pleural effusions without any signs of pneumonia, pulmonary tuberculosis, or lung cancer. Whole-body CT screening interpreted by radiologists showed no signs of malignant tumors. Electrocardiogram (ECG) showed sinus rhythm, low QRS voltage, slight PR depression in leads II, III, aVF, and V3–6, and PR elevation in lead aVR.

Fig. 1. (A) Initial chest X-ray showing the enlarged cardio-thoracic ratio of 76.3% and bilateral pleural effusions. (B) Chest computed tomography showing remarkable pericardial and bilateral pleural effusions. (C) Transthoracic echocardiogram showing remarkable pericardial effusion and collapse sign of left atrium (arrow). (D) Chest X-ray just before discharge with residual left pleural effusion (arrow). (E) Chest X-ray two months after discharge showing that the left pleural effusion disappeared (arrow).

Fig. 2. Initial electrocardiogram showing sinus rhythm, low QRS voltage, slight PR depression in leads II, III, aVF, and V3–6, and PR elevation in lead aVR.
depression in leads II, III, aVF, and V3–6, and PR elevation in lead aVR, implying the presence of pericarditis (Fig. 2). Transthoracic echocardiogram demonstrated remarkable pericardial effusion and collapse signs of right and left atrium, despite a normal left ventricular ejection fraction of over 60% (Fig. 1C). Blood testing revealed that C-reactive protein (CRP) (3.27 mg/dL) and brain natriuretic peptide (113.5 pg/mL) were elevated whereas other parameters including troponin T (0.009 ng/mL), creatine kinase (CK) (136 U/L), CKMB (7 U/L), white blood cell counts, electrolytes, antinuclear antibodies, and thyroid function were normal. Based on these findings, she was diagnosed with pericarditis and peritonamode. The normal ventricular wall motion and myocardial enzyme levels did not show the presence of myocarditis.

After admission, percutaneous pericardial drainage was performed, and her cardiac output recovered from 2.91 L/min to 3.73 L/min by removal of 400 mL of pericardial effusion. Despite the recovery of cardiac function, bilateral pleural effusions remained, and the shortness of breath of the patient was not well improved. Therefore, on the 2nd and 6th day of admission, right and left thoracic percutaneous drainsages were performed, respectively. The drained pericardial and bilateral pleural effusions were all exudative and showed no signs of either malignant disease or bacterial infection including Mycobacterium tuberculosis (Table 1). The analysis of paired serum did not show a significant elevation of specific viral antibodies. Finally, she was diagnosed with subacute pericarditis probably associated with the COVID-19 vaccination.

After administration of 0.5 mg/day of colchicine was started, CRP level decreased as well as pericardial and pleural effusions. On the 17th day of admission, she was discharged from our hospital with a residual left pleural effusion (Fig. 1D). She had an uneventful course after discharge, and two months later, we confirmed that her pericardial and pleural effusions disappeared (Fig. 1E). The timeline of this case is summarized in Online Fig. 1.

**Discussion**

To the best of our knowledge, this is the first report of COVID-19 vaccine-associated pleuroperticarditis. The US Centers for Disease Control and Prevention reported that myocarditis/pericarditis rates were as rare as 12.6 cases per million doses of second-dose mRNA vaccine among individuals 12 to 39 years of age and that the risk of myocarditis/pericarditis was higher for males than females and for the young than the elderly [3]. Our case of an 88-year-old female patient who presented with pericarditis following BNT162b2 vaccination is relatively rare in terms of sex and age. Moreover, the patient experienced bilateral pleuritis simultaneously with pericarditis, which has not been reported in the literature to date.

Although there are no specific criteria for the diagnosis of COVID-19 vaccine-associated pericarditis, we applied the European Society of Cardiology guideline of pericardial disease, as with most of the previous case reports [4–7]. The diagnosis of acute pericarditis is based on the major findings of chest pain, pericardial friction rub, ECG changes, and pericardial effusion, and on the additional supporting findings of the elevation of inflammation marker and the imaging evidence of pericardial inflammation [4]. However, in this case, her age of 88-years might have masked typical chest pain, and a large amount of pericardial effusion might have muted the friction rub. Although the clinical course was atypical and subacute, the slight changes in ECG, pericardial effusion, and the elevated CRP level helped the diagnosis. The etiology of acute pericarditis is generally classified as infectious causes such as bacterial, viral, and fungal and non-infectious causes such as autoimmune, neoplastic, metabolic, traumatic, and drug-related including vaccines [4]. In the clinical course of this case, we did not find any signs of infectious or non-infectious causes which can cause pericarditis except for BNT162b2 vaccination. Similarly, the bilateral pleural effusions were both exudative but did not show any signs of infection, neoplasm, or other diseases [8]. Thus, she was diagnosed with COVID-19 vaccine-associated pleuroperticarditis.

The bilateral pleural effusions accompanied by pericardial effusion, especially when patients are painless, tend to be considered transudative and often diagnosed as congestive heart failure [9]. However, in our case, the drainage of pericardial and bilateral pleural effusions revealed that all of them were exudative, indicating the presence of concurrent pericarditis and bilateral pleuritis. Although it is difficult to specify its pathophysiology, we can presume two possible explanations: one is the direct spread of inflammation between pericardium and pleura, and the other is a result of systemic inflammation caused by vaccination. Previously, it has been reported that COVID-19 vaccination can induce multi-system inflammation syndrome [10]. Although there is no established treatment, steroids, nonsteroidal anti-inflammatory drugs, and colchicine have been empirically used for COVID-19 vaccine-associated pericarditis in the previous reports [5–7]. In our case, the patient’s condition was stabilized after percutaneous drainages of all effusions, and subsequent administration of colchicine was effective for the prevention of recurrence. The aggressive effusion drainage might be useful not only for diagnosis but also for treatment in the clinical management of COVID-19 vaccine-associated pleuroperticarditis.

In conclusion, we experienced a rare case of an elderly female who presented with subacute pleuroperticarditis following BNT162b2 vaccination. When pericardial and pleural effusions are found after COVID-19 vaccination, even if it is painless, bilateral, and with subacute development, vaccine-associated pleuroperticarditis should be considered as a differential diagnosis. Although there is no established treatment, percutaneous drainage and subsequent colchicine administration could be a treatment option for COVID-19 vaccine-associated pleuroperticarditis.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jccase.2022.04.020.

**Declaration of competing interest**

The authors declare that there is no conflict of interest.

**Table 1**

Characteristics of pericardial and pleural effusions.

| Type          | Serum | Pericardial effusion | Right pleural effusion | Left pleural effusion |
|---------------|-------|----------------------|------------------------|-----------------------|
| Appearance    | –     | Exudative            | Exudative              | Exudative             |
| Protein (g/dL)| 6.4   | 5                    | 3.5                    | 4                     |
| Glucose (mg/dL)| 117  | 108                  | 118                    | 148                   |
| LDH (U/L)     | 241   | 432                  | 117                    | 163                   |
| ADA (U/L)     | –     | 21                   | 7                      | 13                    |
| Rheumatoid factor (IU/mL) | <15   | <15                   | <15                    | <15                   |
| CEA (ng/mL)   | –     | 0.9                  | 0.5                    | 0.6                   |
| CA19-9 (U/mL) | –     | 14.4                 | 1.6                    | 2.2                   |
| Bacterial culture | –   | Negative             | Negative               | Negative              |
| Mycobacterial culture | –   | Negative             | Negative               | Negative              |
| Cytology      | –     | Negative             | Negative               | Negative              |

ADA, adenosine deaminase; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; LDH, lactate dehydrogenase.
Acknowledgments

None.

References

[1] Walsh EE, Frenck Jr RW, Falsey AR, Kitchin N, Absalon J, Curtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 2020;383:2439–50.
[2] Polack FP, Thomas SJ, Kitchin N, Absalon J, Curtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–15.
[3] Bozukurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation 2021;144:471–84.
[4] Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015;36:2921–64.
[5] Mclean K, Johnson Tj. Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: a case report. Acad Emerg Med 2021;28:918–21.
[6] Ashaari S, Sohaib HA, Bolger K. A case report: symptomatic pericarditis post-COVID-19 vaccination. Eur Heart J Case Rep 2021;5:ytab375.
[7] Lazaros G, Anastassopoulos C, Hatziantoniou S, Kalos T, Soulaidopoulos S, Lazarou E, et al. A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States. Vaccine 2021;39:6585–90.
[8] Porcel JM, Light RW. Diagnostic approach to pleural effusion in adults. Am Fam Physician 2006;73:1211–20.
[9] Natanzon A, Kronzon I. Pericardial and pleural effusions in congestive heart failure-anatomical, pathophysiologic, and clinical considerations. Am J Med Sci 2009;338:211–6.
[10] Grome HN, Threlkeld M, Threlkeld S, Newman C, Martinez RB, Reagan-Steiner S, et al. Fatal multisystem inflammatory syndrome in adult after SARS-CoV-2 natural infection and COVID-19 vaccination. Emerg Infect Dis 2021;27:2914–8.